A Pilot Study of Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplantation in Patients With Relapsed/Refractory Hodgkin Lymphoma
Active, no longer recruiting
Phase of Trial: Phase 0
Latest Information Update: 17 Jun 2017
At a glance
- Drugs Lenalidomide (Primary)
- Indications Hodgkin's disease
- Focus Therapeutic Use
- 03 Apr 2016 Planned primary completion date changed from 1 Apr 2016 to 1 Apr 2017 as reported by ClinicalTrials.gov record.
- 03 Apr 2016 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
- 15 Aug 2014 Planned End Date changed from 1 Jun 2016 to 1 Oct 2018 as reported by ClinicalTrials.gov record.